Ignite Creation Date:
2024-05-06 @ 5:43 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05401019
Status:
WITHDRAWN
Last Update Posted:
2022-06-02
First Post:
2022-05-25
Brief Title:
Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder OCD
Sponsor:
Clinical Academic Center 2CA-Braga
Organization:
Clinical Academic Center 2CA-Braga
Study Overview
Official Title:
Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder OCD Randomized Controlled Trial
Status:
WITHDRAWN
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This clinical trial was not approved by the regulatory entities It was reviewed and a new trial was re-submitted
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OCD-RT
Brief Summary:
This is a phase 2 randomized controlled clinical trial to study the efficacy of pramipexol or risperidone in the treatment of refractory ODC patients
This study is a two-parallel-group clinical trial with duration of 28 weeks recruitment phase 4 weeks treatment phase 16 weeks follow-up phase 8 weeks The primary endpoint of this study is the score in the Y-BOCS scale measured between baseline and EOT at week 16
This study is a two-parallel-group clinical trial with duration of 28 weeks recruitment phase 4 weeks treatment phase 16 weeks follow-up phase 8 weeks The primary endpoint of this study is the score in the Y-BOCS scale measured between baseline and EOT at week 16
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-000249-34 | EUDRACT_NUMBER | None | None |